Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

Phase 3

Completed

Conditions: Moderate to Severe Atopic Hand and Foot Dermatitis

Interventions: Drug: Placebo
Drug: dupilumab

First Posted Date: 2020-06-05

Last Posted Date: 2023-12-22

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 133

Registration Number: NCT04417894

Locations: 🇵🇱
Regeneron Study Site, Wroclaw, Poland

REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy

Phase 1

Suspended

Conditions: Severe Aplastic Anemia (SAA)

Interventions: Drug: REGN7257

First Posted Date: 2020-06-01

Last Posted Date: 2024-12-20

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 33

Registration Number: NCT04409080

Locations: 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇫🇷
Hopital Saint-Louis - APHP, Paris, Ile-de-France, France

and more 7 locations

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)

Phase 3

Completed

Conditions: Eosinophilic Esophagitis (EoE)

Interventions: Drug: Dupilumab
Drug: Matching Placebo

First Posted Date: 2020-05-19

Last Posted Date: 2024-08-27

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 102

Registration Number: NCT04394351

Locations: 🇨🇦
Regeneron Study Site, London, Ontario, Canada

Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

Phase 2

Withdrawn

Conditions: Hodgkin Lymphoma

Interventions: Drug: Cemiplimab
Radiation: Involved-site radiotherapy (IS-RT)

First Posted Date: 2020-05-04

Last Posted Date: 2021-01-15

Lead Sponsor: Regeneron Pharmaceuticals

Registration Number: NCT04373083

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Sarilumab
Drug: Placebo

First Posted Date: 2020-03-19

Last Posted Date: 2021-09-23

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 1912

Registration Number: NCT04315298

Locations: 🇺🇸
Regeneron Study Site, Renton, Washington, United States
🇺🇸
Regeneron Study Site 1, New York, New York, United States
🇺🇸
Regeneron Study Site 2, New York, New York, United States

Registry of Asthma Patients Initiating DUPIXENT®

Active, not recruiting

Conditions: Asthma

First Posted Date: 2020-02-27

Last Posted Date: 2025-04-22

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 718

Registration Number: NCT04287621

Locations: 🇺🇸
Clinical Research Specialists, LLC, Kissimmee, Florida, United States
🇺🇸
NorthShore University Health System, Evanston, Illinois, United States
🇺🇸
Northwell Health Division of Allergy & Immunology, Great Neck, New York, United States

and more 125 locations

Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis

Completed

Conditions: Conjunctivitis
Atopic Dermatitis

Interventions: Drug: dupilumab

First Posted Date: 2020-02-27

Last Posted Date: 2023-04-28

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT04287608

Locations: 🇺🇸
Regeneron Study Site, Houston, Texas, United States

Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

Phase 3

Completed

Conditions: Homozygous Familial Hypercholesterolemia

Interventions: Drug: Evinacumab

First Posted Date: 2020-01-18

Last Posted Date: 2024-07-16

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT04233918

Locations: 🇨🇳
Regeneron Research Center, Taipei, Taiwan
🇺🇦
Regeneron Research Site, Kyiv, Ukraine

Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)

Phase 2

Completed

Conditions: CD55-deficient Protein-losing Enteropathy
CHAPLE

Interventions: Drug: Pozelimab

First Posted Date: 2019-12-24

Last Posted Date: 2025-05-15

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT04209634

Locations: 🇹🇷
Regeneron Research Site, Istanbul, Turkey

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid

Phase 2

Completed

Conditions: Bullous Pemphigoid

Interventions: Drug: dupilumab
Drug: Matching Placebo
Drug: Oral corticosteroids (OCS)

First Posted Date: 2019-12-20

Last Posted Date: 2025-02-06

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 98

Registration Number: NCT04206553

Locations: 🇨🇳
Regeneron study Site, Taoyuan City, Taiwan
🇩🇪
Regeneron Study Site 2, Dresden, Saxony, Germany
🇵🇱
Regeneron Study site', Wroclaw, Poland

and more 2 locations

Home Terms & Conditions Privacy Policy